“…In addition, for ILR to develop into a widely used treatment throughout the world, one must not only ensure its efficacy and safety, but also solve the issue of insurance coverage for ILR. La-Anyane et al reported that more than half of the main insurance companies in the United States that have a public coverage statement deny ILR coverage ( 9 ). Furthermore, Rochlin et al indicated that the current relative value unit (RVU) allocation undervalues ILR, introducing inefficiency into breast cancer operations when combined with ILR.…”